Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.44 |
| ▸ | ADH1C | P00326 | 1/20 | 0.44 |
| ▸ | ADH1A | P07327 | 1/20 | 0.44 |
| ▸ | ADH4 | P08319 | 1/20 | 0.44 |
| ▸ | ADH7 | P40394 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983390 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL668300 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL668098 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL7776706 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL5508330 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL5504517 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL15171894 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL41714 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL8421553 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL7174533 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110530055-B | Absorption type water chiller/heater, refill liquid for absorption type water chiller/heater, absorption liquid for absorption type water chiller/heater, and maintenance method | 株式会社克莱瑞斯 | 2021-08-20 | — | — | CN | claimed |
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | claimed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | claimed |
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | disclosed |
| CN-115667626-B | Microfibrous cellulose, dispersion, sheet, laminate, and process for producing microfibrous cellulose | 王子控股株式会社 | 2025-01-10 | — | — | CN | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-7446110-B2 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| EP-0612740-B1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO KK (JP) | 1999-09-22 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5719298-A | REACTING PANTOTHENIC ACID ACETONIDE WITH UREA COMPOUND IN THE PRESENCE OF ACYLATING AGENT | FUJIREBIO INC. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | EPHX1 3100/4885TSHR 4834/4885ALDH1A1 2858/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | EPHX1 3151/4885TSHR 3600/4885ALDH1A1 1971/4885 |
| US-20260092138-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURABLE RESIN COMPOSITION COMPRISING THE COMPOSITION, AND CURED PRODUCT | RER1, RPP30, REV1 | EPHX1 1855/4885TSHR 3522/4885ALDH1A1 1319/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | EPHX1 4176/4885TSHR 1595/4885ALDH1A1 3735/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | EPHX1 4256/4885TSHR 4687/4885ALDH1A1 3174/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885TSHR 3319/4885ALDH1A1 2776/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | EPHX1 3906/4885TSHR 1259/4885ALDH1A1 1800/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885TSHR 3319/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.